Serum albumin

About: Serum albumin is a research topic. Over the lifetime, 16337 publications have been published within this topic receiving 516395 citations. The topic is also known as: blood albumin & ANALBA.

Cyanidin 3-O-beta-D-glucoside suppresses nitric oxide production during a zymosan treatment in rats.

Abstract: Anthocyanins are used for food color, and they are widely distributed in the human diets, suggesting that we ingest considerable amounts of anthocyanins from plant-based daily diets. We have demonstrated that a typical anthocyanin, cyanidin 3-O-beta-D-glucoside (C3G), suppressed the zymosan-induced inflammatory response in rats when it was orally administered. The elevation of the peritoneal exudate NOx, tumor necrosis factor (TNF) alpha interleukin-1beta (IL-1beta), IL-6, and the cytokine-induced neutrophil chemoattractant-1 (CINC-1) concentrations were significantly suppressed by the administration of C3G. The zymosan treatment resulted in an increase in the serum alpha2-macroglobulin and decreases in the serum albumin and transferrin levels, which are recognized as acute phase proteins. However, these levels were normalized by the administration of C3G. The inducible nitric oxide synthase (iNOS) protein level in the peritoneal exudate cells was markedly elevated in the control group treated with zymosan. However, the administration of C3G significantly reduced the level of iNOS in the peritoneal exudate cells. Taken altogether, our findings provide a biochemical basis for the use of C3G as a functional food factor and can also have important implications for the prevention of the NO-mediated inflammatory diseases.

In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells

Abstract: To avoid systemic toxicity of the cytotoxic drug methotrexate (MTX) and to improve tumor selectivity, MTX was bound to human serum albumin (HSA) as a drug carrier. To understand more about the mechanism of action of MTX conjugated to HSA (MTX-HSA), the uptake of MTX-HSA into the cell was determined as well as the effect of MTX-HSA on thymidylate synthase (TS), cell cycle distribution, and cell proliferation. Different uptake kinetics were observed for [(3)H]MTX and [(3)H]MTX-HSA. However, similar uptake kinetics were measured for (125)I-HSA and (125)I-MTX-HSA (2.1 and 1.8 pmol/10(7) cells/h when cells were treated with 10 micro M (125)I-HSA and (125)I-MTX-HSA, respectively), suggesting that MTX-HSA enters the cells by albumin-mediated endocytosis. We observed no effect of MTX-HSA on TS when folate receptor-expressing KB cells were treated for 4 h (IC(50), >50 micro M). However, 24 h after incubation, MTX-HSA inhibited TS with an IC(50) of 6.9 micro M. In addition, we found that MTX-HSA had a delayed effect on the cell cycle compared with MTX and that this effect could be inhibited with the lysosomal inhibitor methylamine, suggesting that MTX-HSA activity is dependent on lysosomal processes. The proliferation of different wild-type and MTX-resistant tumor cell lines was inhibited at IC(50) concentrations between 2 and 78 micro M, respectively. MTX-HSA accumulates in vivo in the tumor tissue. Local concentrations of 18-29 micro M were measured, which are effective antiproliferative concentrations as determined in vitro. We also investigated the antitumor activity of MTX-HSA in vivo in different human tumor xenografts grown s.c. in nude mice. Fourteen tumors from eight different tissues were tested. Nine of 14 tumors (64%) showed a clear response with tumor inhibition, stasis, or regression; 5 of 14 (36%) gave a moderate response with tumor growth delay or no response. In conclusion, MTX-HSA is effectively taken up by the cells via albumin receptor- or folate receptor-mediated endocytosis and time-dependently released as an active compound into the cytosol to exert an inhibiting effect on TS and to induce cell cycle alterations. In vivo, effective concentrations of MTX-HSA were reached in tumor tissue to exhibit antitumor activity.